543712-81-8

Usage

Uses

Used in Agricultural Industry:
2,5-Dichloro-N-(5-methyl-1H-pyrazol-3-yl)-4-pyrimidinamine is used as a herbicide for controlling weeds in various crops and agricultural settings. It functions by inhibiting a key enzyme involved in plant growth and development, which ultimately leads to the death of the target plants.
Used in Pharmaceutical Research:
This chemical has been studied for its potential use in pharmaceuticals, where it may contribute to the development of new drugs or therapies due to its unique chemical structure and properties.
Used in Organic Synthesis:
2,5-Dichloro-N-(5-methyl-1H-pyrazol-3-yl)-4-pyrimidinamine also serves as a molecular building block for the synthesis of other organic compounds, making it valuable in the field of organic chemistry and chemical research.

InChI:InChI=1/C8H7Cl2N5/c1-4-2-6(15-14-4)12-7-5(9)3-11-8(10)13-7/h2-3H,1H3,(H2,11,12,13,14,15)

Upstream product

• 31230-17-8 3-methyl-5-aminopyrazole 
• 5750-76-5 2,4,5-trichloropyrimidine 

Downstream Products

• 1202388-91-7 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)-cyclohexanone oxime 
• 1202388-30-4 5-chloro-N₂-(2,5-dimethyl-4-(morpholinomethyl)phenyl)-N₄-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 
• 1202388-82-6 1-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)ethanone O-2-hydroxyethyl oxime 
• 1202389-42-1 N₂-(4-bromo-2,5-dimethylphenyl)-5-chloro-N₄-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 
• 1202389-43-2 1-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)ethanone 
• 1427295-74-6 C₂₈H₂₇Cl₂F₃N₈O₃ 
• 1427295-73-5 C₂₀H₂₄ClN₇O₂ 
• 1427295-72-4 C₂₀H₂₂ClN₇O₄ 
• 935666-88-9 AZD1480 
• 935666-88-9 5-chloro-N2-[(1R)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 
• 1202389-45-4 4-(4-(5-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-ylamino)-2,5-dimethylphenyl)cyclohexanone 
• 1202389-41-0 N₂-(4-bromo-2,5-dimethylphenyl)-5-chloro-N₄-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 
• 1099727-46-4 (R)-5-chloro-2-[1-(4-fluorophenyl)ethoxy]-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine 
• 1099727-48-6 (S)-5-chloro-2-[1-(4-fluorophenyl)ethoxy]-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of proteolysis targeting chimeras (PRoTACS) for the dual degradation of IGF-1R and SrC

A focused PROTAC library was developed to degrade both IGF-1R and Src proteins, which are associated with various cancers. PROTACs with IGF-1R and Src degradation potentials were synthesized by tethering different inhibitor warhead units and the E3 ligase (CRBN) recruiting-pomalidomide with various linkers. The designed PROTACs 12a–b inhibited the proliferation and migration of MCF7 and A549 cancer cells with low micromolar potency (1–5 μM) in various cellular assays.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted ceteroary compound as well as a composition and a purpose thereof. The substituted ceteroary compound is a compound shown as a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the pharmaceutically acceptable salt of the compound shown as the formula (I) and is used for regulating diseases or disorders mediated by one kind or various kinds of Janus kinase activities. The invention also provides a medicine composition containing the compound and a method of treating or alleviating the disease or disorder degree of a patient by inhibiting the Janus kinase activity.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.

4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by

4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by

Use of ω-transaminase enzyme chemistry in the synthesis of a JAK2 kinase inhibitor

ω-Transaminase enzyme chemistry provides an excellent methodology to build synthetically useful chiral amines from their corresponding ketones. An application of this methodology, providing a long-term commercial manufacturing route to a JAK2 kinase inhibitor, is reported herein.

Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway

The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs. Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor. 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials.

CHEMICAL COMPOUNDS 916-1

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.